Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept Monotherapy Guided by Immune Monitoring
NCT04177095Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Feb 2020
- Primary completion
- Sep 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of belatacept in kidney transplant rejection, sponsored by Massachusetts General Hospital. Primary endpoint: Acute Rejection at 12 months. Started Feb 2020; status: completed.
02
Drugs
belatacept
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT04177095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04177095.